2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factors
2018
Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease
Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz M, Tindle HA, Sico J, Tracy RP, Justice AC, Freiberg MS. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018, 138: 255-265. PMID: 29535090, PMCID: PMC6050082, DOI: 10.1161/circulationaha.117.032647.Peer-Reviewed Original ResearchConceptsRisk of PADIncident PAD eventsPeripheral artery diseaseHuman immunodeficiency virusCD4 cell countTraditional atherosclerotic risk factorsPAD risk factorsAtherosclerotic risk factorsPAD eventsRisk factorsCell countUninfected veteransCD4 cellsArtery diseaseHIV infectionHIV statusViral loadCells/Peripheral artery disease eventsPrior peripheral artery diseaseHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyHIV-1 ribonucleic acidHIV infection statusHIV viral load
2014
Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing
Sigel K, Wisnivesky J, Shahrir S, Brown ST, Justice A, Kim J, Rodriguez-Barradas MC, Akgün KM, Rimland D, Hoo GW, Crothers K. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing. AIDS 2014, 28: 1007-1014. PMID: 24401647, PMCID: PMC4018450, DOI: 10.1097/qad.0000000000000189.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialNLST criteriaCT findingsLung cancerCT scanHIV-Associated Lung Emphysema (EXHALE) studyAbnormal CT scansCD4 cell countChest CT findingsHigh-risk smokersAbnormal CT findingsLung cancer mortalityBalance of benefitsUninfected participantsUninfected veteransAsymptomatic HIVCD4 cellsAbnormal findingsTomography screeningUnadjusted riskHIV statusMultivariable analysisCancer mortalityChest CTClinical evaluation
2009
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDS